Quick Answer
BioXcel Therapeutics, Inc. reported Stockholders Equity of -$95.46 million for fiscal year 2025.
BioXcel Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$95.46M | -2.5% |
| 2024 | -$93.10M | -64.8% |
| 2023 | -$56.51M | -173.6% |
| 2022 | $76.78M | -65.4% |
| 2021 | $221.67M | +7.2% |
| 2020 | $206.70M | +668.5% |
| 2019 | $26.89M | -30.8% |
| 2018 | $38.89M | +4060.2% |
| 2017 | -$982.0K | -212.7% |
| 2017 | -$314.0K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$88.92M | -3.8% | +17.4% |
| June 30, 2025 | -$107.67M | -44.9% | -19.4% |
| March 31, 2025 | -$90.17M | -24.6% | +3.1% |
| December 31, 2024 | -$93.10M | -64.8% | -8.7% |
| September 30, 2024 | -$85.63M | -110.9% | -15.3% |
| June 30, 2024 | -$74.30M | -1367.1% | -2.7% |
| March 31, 2024 | -$72.36M | -236.5% | -28.1% |
| December 31, 2023 | -$56.51M | -173.6% | -39.2% |
- BioXcel Therapeutics, Inc. showed a decrease of -2.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2017–2025 period, BioXcel Therapeutics, Inc.’s stockholders equity has declined by 30302.2% (from -$314.0 thousand to -$95.46 million).
- The most recent figure is from BioXcel Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: